Aimmune’s Peanut Allergy Drug Desensitizes Patients in Trial

Aimmune Therapeutics Inc.’s treatment for peanut allergy successfully desensitized patients in a midstage trial. If eventually approved, it would be the first oral drug for the condition.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.